Introduction
Materials and methods
Patients and tissue samples
Patients, total | Gender, male/female | Age, years | Disease duration, years | Rheumatoid factor, +/- | ESR, mm/hour | CRPa, mg/L | Number of ARA criteria for RA | Concomitant medication (number) |
---|---|---|---|---|---|---|---|---|
Rheumatoid arthritis | ||||||||
12 | 3/9 | 65.9 ± 2.9 | 15.8 ± 4.2 | 10/2 | 42.6 ± 6.2 | 31.9 ± 7.2 | 5.3 ± 2.1 | MTX (5) |
Prednis. (10) | ||||||||
Sulfas. (3) | ||||||||
NSAIDs (9) | ||||||||
Osteoarthritis | ||||||||
10 | 2/8 | 71.9 ± 2.0 | 6.2 ± 2.7 | 1/9 | 22.9 ± 4.0 | 7.6 ± 2.9 | 0.1 ± 0.1 | NSAIDs (4) |
None (7) | ||||||||
Normal controls | ||||||||
9 | 7/2 | 49.9 ± 6.7 | 0.4 ± 0.3 | ND | ND | ND | 0.0 ± 0.0 | None |
Isolation of total RNA
Microarray data analysis
Real-time reverse transcription-polymerase chain reaction
Statistical analysis of gene expression variance
Analysis of inter-individual gene expression variances
Mapping of probesets onto gene names
Statistical KEGG analysis
Results
Analysis of inter-individual gene expression variances in rheumatoid arthritis, osteoarthritis, and normal control synovial membrane
Real-time reverse transcription-polymerase chain reaction validation
KEGG pathways identified in the comparison between rheumatoid arthritis and normal control
Pathways significantly affected by inter-individual gene expression variances in rheumatoid arthritis
KEGG identification number | Pathway/complex | B (E) | χ2 | P value | Affected genes | |
---|---|---|---|---|---|---|
1 | hsa04060 | Cytokine–cytokine receptor interactiona | 14 (8) | 4.56 | 0.12 |
CXCL13, IFNA8, FNAR2, IL2RG, IL4, IL8, IL13, CXCL10, IL21R, TNFRSF17, TGFBR2, CD27, TNFRSF25, ACVR1B
|
2 | hsa04010 | MAPK signaling pathwaya | 13 (8) | 3.32 | 0.22 |
CHP, AKT2, MAP3K7IP2, PLA2G2D, IKBKB, NTRK2, PRKACA, MAPK8, PRKX, TGFBR2, CACNB1, FGF18, ACVR1B
|
2a | hsa04010 | MAPK signaling pathwaya (classical + JNK/p38 MAPK sub-pathway) | 13 (7) | 4.39 | 0.13 |
CHP, AKT2, MAP3K7IP2, PLA2G2D, IKBKB, NTRK2, PRKACA, MAPK8, PRKX, TGFBR2, CACNB1, FGF18, ACVR1B
|
3 | hsa05212 | Pancreatic cancera | 9 (2) | 20.29 | <0.01 |
E2F3, AKT2, IKBKB, SMAD2, MAPK8, BCL2L1, STAT1, TGFBR2, ACVR1B
|
4 | hsa04620 | Toll-like receptor signaling pathwaya | 9 (3) | 14.01 | <0.01 |
AKT2, MAP3K7IP2, IFNA8, IFNAR2, IKBKB, IL8, CXCL10, MAPK8, STAT1
|
5 | hsa04660 | T-cell receptor signaling pathwaya | 7 (3) | 5.98 | 0.05 |
CHP, AKT2, IKBKB, IL4, RHOA, PDK1, PLCG1
|
6 | hsa04664 | Fc epsilon receptor I signaling pathwaya | 7 (2) | 9.53 | 0.01 |
AKT2, PLA2G2D, IL4, IL13, PDK1, PLCG1, MAPK8
|
7 | hsa04520 | Adherens junctiona | 6 (2) | 5.56 | 0.07 |
CSNK2A1, RHOA, SMAD2, TGFBR2, ACVR1B, CDH1
|
8 | hsa05220 | Chronic myeloid leukemiaa | 6 (2) | 5.73 | 0.06 |
E2F3, IKBKB, BCL2L1, TGFBR2, ACVR1B, AKT2
|
9 | hsa04350 | TGF-β signaling pathwaya | 5 (3) | 1.86 | 0.38 |
RHOA, SMAD2, TGFBR2, ACVR1B, ZFYVE9
|
9a | hsa04350 | TGF-β signaling pathwaya (classical TGF-β sub-pathway) | 5 (2) | 6.7 | 0.05 |
RHOA, SMAD2, TGFBR2, ACVR1B, ZFYVE9
|
10 | hsa04210 | Apoptosisa | 5 (3) | 2.25 | 0.34 |
AKT2, IKBKB, PRKACA, BCL2L1, CHP
|
10a | hsa04210 | Apoptosisa (anti-apoptotic sub-complex) | 5 (1) | 6.7 | 0.03 |
AKT2, IKBKB, PRKACA, BCL2L1, CHP
|
Pathways significantly affected by inter-individual gene expression variances in normal control
KEGG identification number | Pathway/complex | B (E) | χ2 | P value | Affected genes | |
---|---|---|---|---|---|---|
1 | hsa03010 | Ribosomea | 8 (3) | 27.62 | <0.01 |
RPL7, RPL9, RPL21, RPL27, RPL30, RPS6, RPS10, RPS12
|
2 | hsa04110 | Cell cyclea | 7 (4) | 13.11 | <0.01 |
CDKN1A, E2F1, GADD45B, ATM, SKP1A, CCNA2, CDC2
|
3 | hsa04310 | Wnt signaling pathwaya | 7 (5) | 7.8 | 0.01 |
CACYBP, PPP2R1B, PRKACB, PSEN1, SKP1A, TBL1XR1, FZD1
|
4 | hsa04640 | Hematopoietic cell lineagea | 4 (3) | 4.15 | 0.15 |
CSF1, EPOR, FLT3LG, ITGA4
|
5 | hsa05010 | Alzheimer diseasea | 3 (1) | 13.3 | <0.01 |
GAPDH, LRP1, PSEN1
|
6 | hsa01510 | Neurodegenerative disordersa | 3 (1) | 8.18 | 0.01 |
GAPDH, NR4A2, PSEN1
|
KEGG pathways identified in the comparison between osteoarthritis and normal control
Pathways significantly affected by inter-individual gene expression variances in osteoarthritis
KEGG identification number | Pathway/complex | B (E) | χ2 | P value | Affected genes | |
---|---|---|---|---|---|---|
1 | hsa04310 | Wnt signaling pathway | 7 (4) | 3.44 | 0.21 |
CSNK2A1, SMAD2, PPP3CB, PRKACA, TBL1X, BTRC, RBX1
|
1a | hsa04310 | Wnt signaling pathway (canonical sub-pathway) | 6 (3) | 4.56 | 0.12 |
CSNK2A1, BTRC, SMAD2, PRKACA, TBL1X, RBX1
|
2 | hsa04210 | Apoptosisa | 6 (2) | 8.13 | 0.01 |
AKT2, IKBKB, PP3CB, PRKACA, RKAR2A, BCL2L
|
3 | hsa03010 | Ribosomea | 5 (2) | 3.99 | 0.16 |
RPL18, RPL35A, RPL38, RPS10, RPL14
|
3a | hsa03010 | Ribosomea (large subunit) | 4 (1) | 6.49 | 0.04 |
RPL18, RPL35A, RPL38, RPL14
|
4 | hsa04520 | Adherens junctiona | 5 (2) | 5.57 | 0.07 |
CSNK2A1, SMAD2, ACP1, TGFBR2, YES1
|
5 | hsa05212 | Pancreatic cancera | 5 (1) | 6.22 | 0.04 |
AKT2, IKBKB, SMAD2, BCL2L1, TGFBR2
|
6 | hsa04120 | Ubiquitin-mediated proteolysisa | 4 (2) | 8.12 | 0.01 |
ANAPC5, UBE2D2, BTRC, RBX1
|
7 | hsa05050 | Dentatorubropallidoluysian atrophya | 3 (1) | 19.79 | <0.01 |
ATN1, RERE, MAGI1
|
Pathways significantly affected by inter-individual gene expression variances in normal control
KEGG identification number | Pathway/complex | B (E) | χ2 | P value | Affected genes | |
---|---|---|---|---|---|---|
1 | hsa04310 | Wnt signaling pathway | 8 (3) | 6.55 | 0.04 |
CSNK1A1, DKK2, JUN, MYC, PPP2R1B, PRKACB, WNT5B, FZD1
|
2 | hsa05120 | Epithelial cell signaling in Helicobacter pylori infectiona | 5 (2) | 7.97 | 0.01 |
JUN, NFKBIA, ATP6V1C1, ADAM17, ATP6V0D1
|
3 | hsa05211 | Renal cell carcinomaa | 5 (2) | 7.75 | 0.01 |
AKT2, HGF, JUN, TCEB1, VEGFA
|
4 | hsa04620 | Toll-like receptor signaling pathwaya | 5 (2) | 4.43 | 0.12 |
AKT2, JUN, NFKBIA, TLR7, STAT1
|
KEGG pathways identified in the comparison between rheumatoid arthritis and osteoarthritis
Pathways significantly affected by inter-individual gene expression variances in rheumatoid arthritis
KEGG identification number | Pathway/complex | B (E) | χ2 | P value | Affected genes | |
---|---|---|---|---|---|---|
1 | hsa04916 | Melanogenesisa | 6 (3) | 6.53 | 0.03 |
ADCY2, LEF1, PRKCB1, PRKX, TCF7, WNT8B
|
2 | hsa04662 | B-cell receptor signaling pathwaya | 5 (2) | 9.72 | 0.01 |
MALT1, PIK3CD, PLCG2, PRKCB1, CD72
|
3 | hsa04370 | VEGF signaling pathwaya | 4 (2) | 4.09 | 0.15 |
PLA2G2D, PIK3CD, PLCG2, PRKCB1
|
Pathways significantly affected by inter-individual gene expression variances in osteoarthritis
KEGG identification number | Pathway/complex | B (E) | χ2 | P value | Affected genes | |
---|---|---|---|---|---|---|
1 | hsa00190 | Oxidative phosphorylationa | 10 (1) | 75.6 | <0.01 |
COX5B, NDUFA6, NDUFA8, NDUFB2, NDUFB4, SDHC, NDUFB6, aNDUFC1, NDUFA13, ATP5G3
|
2 | hsa04010 | MAPK signaling pathwaya | 5 (2) | 3.8 | 0.17 |
DUSP5, RASGRP3, FAS, MAPK11, TAOK1
|
2a | hsa04010 | MAPK signaling pathwaya (JNK/p38 MAPK sub-pathway) | 4 (1) | 6.54 | 0.03 |
DUSP5, FAS, MAPK11, TAOK1
|
3 | hsa00790 | Folate biosynthesisa | 3 (0) | 22.03 | <0.01 |
ASCC3, SETX, SMARCA5
|
4 | hsa00500 | Starch and sucrose metabolisma | 3 (1) | 7.86 | 0.01 |
ASCC3, SETX, SMARCA5
|